» Articles » PMID: 22240838

Long-lasting Inhibitory Effects of Cyclosporin A, but Not Tacrolimus, on OATP1B1- and OATP1B3-mediated Uptake

Overview
Publisher Elsevier
Date 2012 Jan 14
PMID 22240838
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclosporin A (CsA) causes a number of clinically relevant drug-drug interactions (DDIs) by inhibiting OATP1B1 and OATP1B3. In the present study, long-lasting inhibitory effects of CsA on these transporters were examined in comparison to tacrolimus (TCR). OATP1B1- and OATP1B3-expressing HEK293T cells, OATP1B1-expressing MDCK II cells, and human hepatocytes were preincubated with CsA or TCR, and uptake studies were carried out in their presence or absence. Western blot or immunohistochemical studies were done in OATP1B1-expressing HEK293T cells. The pretreatment of OATP1B1- and OATP1B3-expressing cells with 0.5-10 µM CsA, but not TCR, resulted in a reduction in their activity, even after washing out CsA from the incubation media. Preincubating the cells with CsA significantly enhanced its inhibitory effects on OATP1B1 and OATP1B3 by coincubation at 0.1-1 µM. Preincubation with 1 µM CsA caused a reduction in OATP1B1 activity for at least 18 h after its removal. The expression of OATP1B1 was not affected by incubation with CsA and no obvious change in its intracellular localization was observed. The long-lasting inhibition by CsA was also observed in human hepatocytes. Thus, CsA has a long-lasting inhibitory effect on OATP1B1 and OATP1B3. It may attribute to the clinically relevant DDIs between OATP substrates and CsA.

Citing Articles

Assessing -Inhibition of OATP1B1 and OATP1B3 by Calcineurin and/or PPIase Inhibitors and Global Identification of OATP1B1/3-Associated Proteins.

Powell J, Kayesh R, Ballesteros-Perez A, Alam K, Niyonshuti P, Soderblom E Pharmaceutics. 2024; 16(1).

PMID: 38258074 PMC: 10818623. DOI: 10.3390/pharmaceutics16010063.


Sensitivity of Human Induced Pluripotent Stem Cells and Thereof Differentiated Kidney Proximal Tubular Cells towards Selected Nephrotoxins.

Mboni-Johnston I, Kouidrat N, Hirsch C, Weber A, Meissner A, Adjaye J Int J Mol Sci. 2024; 25(1).

PMID: 38203251 PMC: 10779191. DOI: 10.3390/ijms25010081.


Identification of the Stapled α-Helical Peptide ATSP-7041 as a Substrate and Strong Inhibitor of OATP1B1 In Vitro.

Ishikawa R, Saito K, Misawa T, Demizu Y, Saito Y Biomolecules. 2023; 13(6).

PMID: 37371582 PMC: 10296347. DOI: 10.3390/biom13061002.


Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics.

Brunet M, Pastor-Anglada M Pharmaceutics. 2022; 14(9).

PMID: 36145503 PMC: 9503558. DOI: 10.3390/pharmaceutics14091755.


In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.

Chu X, Chan G, Houle R, Lin M, Yabut J, Fandozzi C AAPS J. 2022; 24(3):45.

PMID: 35314909 DOI: 10.1208/s12248-021-00677-8.